David Hoang
Stock Analyst at Citigroup
(2.40)
# 2,419
Out of 4,711 analysts
28
Total ratings
55%
Success rate
-1.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $30 → $23 | $16.87 | +36.34% | 4 | Aug 8, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $176 → $160 | $118.97 | +34.49% | 5 | Aug 8, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $150 → $158 | $135.42 | +16.67% | 4 | Aug 2, 2024 | |
| DNLI Denali Therapeutics | Maintains: Buy | $26 → $32 | $21.45 | +49.18% | 2 | Aug 2, 2024 | |
| ABOS Acumen Pharmaceuticals | Initiates: Buy | $7 | $1.85 | +278.38% | 1 | Jul 25, 2024 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $48 | $34.28 | +40.02% | 1 | Jun 21, 2024 | |
| SAGE Sage Therapeutics | Initiates: Sell | $8 | $5.61 | +42.60% | 1 | May 29, 2024 | |
| XENE Xenon Pharmaceuticals | Maintains: Buy | $62 → $60 | $38.63 | +55.32% | 2 | May 10, 2024 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $127 → $125 | $90.73 | +37.77% | 3 | May 7, 2024 | |
| SLDB Solid Biosciences | Initiates: Buy | $16 | $4.16 | +284.62% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $5.75 | +178.26% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $220 | $245.44 | -10.37% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $19.45 | +311.31% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 | $0.84 | +257.14% | 1 | Dec 7, 2022 |
ACADIA Pharmaceuticals
Aug 8, 2024
Maintains: Buy
Price Target: $30 → $23
Current: $16.87
Upside: +36.34%
Sarepta Therapeutics
Aug 8, 2024
Maintains: Neutral
Price Target: $176 → $160
Current: $118.97
Upside: +34.49%
Neurocrine Biosciences
Aug 2, 2024
Maintains: Neutral
Price Target: $150 → $158
Current: $135.42
Upside: +16.67%
Denali Therapeutics
Aug 2, 2024
Maintains: Buy
Price Target: $26 → $32
Current: $21.45
Upside: +49.18%
Acumen Pharmaceuticals
Jul 25, 2024
Initiates: Buy
Price Target: $7
Current: $1.85
Upside: +278.38%
Harmony Biosciences Holdings
Jun 21, 2024
Initiates: Buy
Price Target: $48
Current: $34.28
Upside: +40.02%
Sage Therapeutics
May 29, 2024
Initiates: Sell
Price Target: $8
Current: $5.61
Upside: +42.60%
Xenon Pharmaceuticals
May 10, 2024
Maintains: Buy
Price Target: $62 → $60
Current: $38.63
Upside: +55.32%
Axsome Therapeutics
May 7, 2024
Maintains: Buy
Price Target: $127 → $125
Current: $90.73
Upside: +37.77%
Solid Biosciences
Mar 15, 2024
Initiates: Buy
Price Target: $16
Current: $4.16
Upside: +284.62%
Mar 7, 2024
Initiates: Buy
Price Target: $16
Current: $5.75
Upside: +178.26%
Apr 26, 2023
Initiates: Neutral
Price Target: $220
Current: $245.44
Upside: -10.37%
Apr 26, 2023
Initiates: Outperform
Price Target: $80
Current: $19.45
Upside: +311.31%
Dec 7, 2022
Downgrades: Neutral
Price Target: $3
Current: $0.84
Upside: +257.14%